+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
HAE Treatments Market - Global Forecast 2026-2032- Product Image
HAE Treatments Market - Global Forecast 2026-2032- Product Image
Sale

HAE Treatments Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6119217
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The HAE Treatments Market is projected to reach USD 4.69 Billion in 2026. It is expected to continue growing at a CAGR of 12.75%, reaching USD 9.85 Billion by 2032.

HAE Treatments: Executive Summary and Strategic Context

Hereditary angioedema (HAE) is a rare, potentially life-threatening disorder most commonly associated with deficient or dysfunctional C1-inhibitor activity, although additional genetic mechanisms are recognized. Treatment strategy centers on rapid management of acute attacks, prevention of attacks when clinically appropriate, and individualized planning for procedures and long-term care. Clinical decisions depend on attack pattern, disease severity, treatment access, administration preferences, comorbidities, age, and local regulatory and reimbursement conditions.

Treatment Is Shifting Toward Proactive, Patient-Centered Care

HAE management has moved beyond reliance on emergency treatment alone. Contemporary care increasingly emphasizes individualized long-term prophylaxis, early self-administration, treatment plans for medical and dental procedures, and education that helps patients recognize attacks promptly. The availability of intravenous, subcutaneous, and oral approaches has broadened treatment discussions, while guideline-based care continues to stress access to on-demand therapy for every patient at risk of an attack. Shared decision-making is especially important because treatment burden, dosing frequency, route of administration, and patient preference can materially affect persistence and quality of life.

Artificial Intelligence Can Improve Detection, Coordination, and Evidence Generation

Artificial intelligence may support HAE care through symptom-pattern analysis, clinical decision support, patient-reported outcome monitoring, medical-record abstraction, and identification of delayed or missed diagnoses. Applications must be developed carefully because HAE is rare, symptoms overlap with other forms of angioedema, and datasets may underrepresent patients across ancestry, age, sex, and healthcare settings. Validated tools could help prioritize specialist referral, improve attack documentation, identify adherence barriers, and support pharmacovigilance, but they should complement-not replace-specialist judgment, laboratory testing, genetic assessment when indicated, and patient consent.

Regional Priorities Differ Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America generally benefits from established specialty networks, diagnostic capabilities, and multiple treatment modalities, although affordability, insurance restrictions, and uneven access remain important concerns. Europe has strong clinical guidance and specialist expertise, but access differs across national reimbursement systems and cross-border care pathways. Asia-Pacific combines advanced HAE services in several economies with substantial diagnostic and treatment gaps elsewhere, making education and referral infrastructure central priorities. Latin America faces variation in laboratory availability, specialist concentration, and public-sector access. In the Middle East, specialized centers and national health-system capacity coexist with differences in coverage and awareness. Africa requires expanded recognition of HAE, reliable confirmatory testing, specialist training, and sustainable access to acute and preventive treatment.

Global Groups Highlight Different Access, Policy, and Collaboration Needs

ASEAN members face varied diagnostic capacity, reimbursement systems, and specialist distribution, supporting the value of regional education and referral coordination. BRICS countries span highly diverse healthcare infrastructures and can benefit from stronger rare-disease registries, local evidence generation, and technology transfer. The European Union provides opportunities for harmonized standards, cross-border expertise, and coordinated rare-disease networks, while national reimbursement decisions remain influential. G7 countries generally possess substantial research and specialty-care capabilities but continue to address affordability, health inequities, and diagnostic delay. GCC states may leverage centralized healthcare planning and specialist hubs to improve coordinated care. NATO members represent a diverse healthcare group in which continuity of care, emergency preparedness, and access for mobile populations are practical considerations.

Country-Level HAE Priorities Range From Diagnosis to Treatment Continuity

Australia can strengthen specialist access across geographically dispersed populations and support coordinated rare-disease care. Brazil and Mexico need continued attention to diagnostic recognition, regional referral pathways, and equitable public access. Canada and the United States have advanced specialty resources but must address cost, coverage variation, and geographic disparities. China and India would benefit from broader clinician awareness, confirmatory testing, and specialist-network development. France, Germany, Italy, and Spain have established European expertise, with ongoing priorities around consistent reimbursement, referral coordination, and patient-centered treatment selection. Japan and South Korea can build on sophisticated healthcare systems by expanding awareness and improving access outside major centers. The United Kingdom has strong specialist capabilities, while commissioning, regional variation, and timely diagnosis remain relevant operational issues. Russia faces the need to sustain diagnostic and treatment pathways across a geographically extensive system.

Industry Leaders Should Prioritize Reliable Access, Evidence, and Patient Experience

Leaders should align product development and service design with the full HAE care pathway: diagnosis, attack treatment, prophylaxis, procedural planning, follow-up, and psychosocial support. Evidence programs should include patient-reported outcomes, real-world safety, diverse populations, pediatric and pregnancy-relevant evidence where appropriate, and comparisons that reflect meaningful treatment burden. Organizations should work with clinicians and patient communities to improve disease recognition, support self-management, and reduce delays in referral. Access strategies should account for reimbursement differences, cold-chain or administration requirements, emergency availability, and continuity during travel or care transitions. Digital tools, including AI-enabled solutions, should undergo clinical validation, privacy review, bias assessment, and post-deployment monitoring.

Methodology Combines Clinical Evidence, Policy Review, and Geographic Synthesis

This executive summary uses a qualitative synthesis of established clinical concepts in HAE, including disease biology, acute-treatment principles, long-term prophylaxis, diagnostic pathways, and patient-centered care. Geographic and group observations are framed around publicly recognized differences in healthcare infrastructure, specialist availability, diagnostic capacity, reimbursement, and rare-disease policy. The assessment avoids market estimation and does not infer treatment uptake or commercial performance. Interpretations should be validated against current local guidelines, regulatory decisions, reimbursement policies, epidemiological registries, and peer-reviewed evidence before being used for operational or investment decisions.

Better HAE Outcomes Depend on Earlier Recognition and Individualized Continuity of Care

The central strategic priority in HAE treatment is dependable, individualized care across the entire disease journey. Earlier diagnosis, access to effective on-demand therapy, appropriate preventive treatment, patient education, and coordinated specialist support can reduce avoidable burden and improve confidence in self-management. Progress will depend on collaboration among healthcare professionals, patients, policymakers, payers, researchers, and technology developers. Regional adaptation is essential: solutions must reflect local diagnostic resources, financing structures, geography, and health-system capacity while maintaining consistent standards for safety, evidence, and patient choice.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. HAE Treatments Market, by Therapy Mechanism
7.1. Introduction
7.2. Bradykinin Receptor Antagonist
7.3. C1 Inhibitor Replacement
7.3.1. Plasma Derived C1 Inhibitor
7.3.2. Recombinant C1 Inhibitor
7.4. Kallikrein Inhibitor
7.4.1. Ecallantide
7.4.2. Lanadelumab
8. HAE Treatments Market, by Product Type
8.1. Introduction
8.2. On Demand
8.3. Prophylactic
9. HAE Treatments Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Subcutaneous
10. HAE Treatments Market, by End User
10.1. Introduction
10.2. Clinic
10.3. Home Healthcare
10.4. Hospital
11. HAE Treatments Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. HAE Treatments Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Retail Pharmacy
12.4. Specialty Pharmacy
13. HAE Treatments Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. HAE Treatments Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. HAE Treatments Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Adverum Biotechnologies, Inc.
17.2. Akari Therapeutics plc
17.3. Alnylam Pharmaceuticals, Inc.
17.4. Argenx SE
17.5. AstraZeneca plc
17.6. Attune Pharmaceuticals, Inc.
17.7. BioCryst Pharmaceuticals, Inc.
17.8. BioMarin Pharmaceutical Inc.
17.9. CSL Behring GmbH
17.10. Editas Medicine, Inc.
17.11. F. Hoffmann-La Roche Ltd.
17.12. Homology Medicines, Inc.
17.13. IBio, Inc.
17.14. KalVista Pharmaceuticals, Inc.
17.15. Moderna, Inc.
17.16. Novartis AG
17.17. Pharming Group N.V.
17.18. Regeneron Pharmaceuticals, Inc.
17.19. Sangamo Therapeutics, Inc.
17.20. Sarepta Therapeutics, Inc.
17.21. Takeda Pharmaceutical Company Limited
17.22. Vertex Pharmaceuticals Incorporated
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global HAE Treatments Market, Years Considered for the Study
FIGURE 2. Global HAE Treatments Market, Research Design
FIGURE 3. Global HAE Treatments Market, Research Framework
FIGURE 4. Global HAE Treatments Market, Data Triangulation
FIGURE 5. Global HAE Treatments Market Size, 2017-2032 (USD Million)
FIGURE 6. Global HAE Treatments Market Size, by Therapy Mechanism, 2025 vs 2032 (%)
FIGURE 7. Global HAE Treatments Market Size, by Therapy Mechanism, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global HAE Treatments Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 9. Global HAE Treatments Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global HAE Treatments Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global HAE Treatments Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global HAE Treatments Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global HAE Treatments Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global HAE Treatments Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 15. Global HAE Treatments Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global HAE Treatments Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global HAE Treatments Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global HAE Treatments Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global HAE Treatments Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global HAE Treatments Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global HAE Treatments Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global HAE Treatments Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global HAE Treatments Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global HAE Treatments Market Segmentation & Coverage
TABLE 2. Global HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 3. Global HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 4. Global Bradykinin Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Bradykinin Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Bradykinin Receptor Antagonist Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global C1 Inhibitor Replacement Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global C1 Inhibitor Replacement Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global C1 Inhibitor Replacement Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Plasma Derived C1 Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Plasma Derived C1 Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Plasma Derived C1 Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Recombinant C1 Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Recombinant C1 Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Recombinant C1 Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Kallikrein Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Kallikrein Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Kallikrein Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Ecallantide Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Ecallantide Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Ecallantide Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Lanadelumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Lanadelumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Lanadelumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 26. Global On Demand Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global On Demand Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global On Demand Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Prophylactic Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Prophylactic Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Prophylactic Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 33. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 40. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 50. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 60. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global HAE Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific HAE Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 79. North America HAE Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. North America HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 81. North America HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 82. North America HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 83. North America HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 84. North America HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 85. North America HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. North America HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 87. North America HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. Latin America HAE Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Latin America HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 90. Latin America HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 91. Latin America HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 92. Latin America HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 93. Latin America HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 94. Latin America HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 95. Latin America HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 96. Latin America HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 97. Europe HAE Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Europe HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 99. Europe HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 100. Europe HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 101. Europe HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 102. Europe HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 103. Europe HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 104. Europe HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 105. Europe HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 106. Middle East HAE Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Middle East HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 108. Middle East HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 109. Middle East HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 110. Middle East HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 111. Middle East HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 112. Middle East HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 113. Middle East HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 114. Middle East HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 115. Africa HAE Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Africa HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 117. Africa HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 118. Africa HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 119. Africa HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 120. Africa HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 121. Africa HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. Africa HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 123. Africa HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. Global HAE Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. ASEAN HAE Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. ASEAN HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 127. ASEAN HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 128. ASEAN HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 129. ASEAN HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 130. ASEAN HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 131. ASEAN HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 132. ASEAN HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 133. ASEAN HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. GCC HAE Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. GCC HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 136. GCC HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 137. GCC HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 138. GCC HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 139. GCC HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 140. GCC HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. GCC HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 142. GCC HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 143. European Union HAE Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. European Union HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 145. European Union HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 146. European Union HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 147. European Union HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 148. European Union HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 149. European Union HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. European Union HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 151. European Union HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 152. BRICS HAE Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 153. BRICS HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 154. BRICS HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 155. BRICS HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 156. BRICS HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 157. BRICS HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 158. BRICS HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. BRICS HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 160. BRICS HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. G7 HAE Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 162. G7 HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 163. G7 HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 164. G7 HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 165. G7 HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 166. G7 HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 167. G7 HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 168. G7 HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 169. G7 HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. NATO HAE Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 171. NATO HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 172. NATO HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 173. NATO HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 174. NATO HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 175. NATO HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 176. NATO HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. NATO HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 178. NATO HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 179. Global HAE Treatments Market Size, by Country, 2017-2032 (USD Million)
TABLE 180. United States HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 181. United States HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 182. United States HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 183. United States HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 184. United States HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 185. United States HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 186. United States HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. United States HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 188. United States HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 189. Canada HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 190. Canada HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 191. Canada HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 192. Canada HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 193. Canada HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 194. Canada HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 195. Canada HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. Canada HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 197. Canada HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 198. Mexico HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 199. Mexico HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 200. Mexico HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 201. Mexico HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 202. Mexico HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 203. Mexico HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 204. Mexico HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Mexico HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 206. Mexico HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 207. Brazil HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 208. Brazil HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 209. Brazil HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 210. Brazil HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 211. Brazil HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 212. Brazil HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 213. Brazil HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 214. Brazil HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 215. Brazil HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 216. United Kingdom HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 217. United Kingdom HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 218. United Kingdom HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 219. United Kingdom HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 220. United Kingdom HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 221. United Kingdom HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 222. United Kingdom HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 223. United Kingdom HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 224. United Kingdom HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 225. Germany HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 226. Germany HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 227. Germany HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 228. Germany HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 229. Germany HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 230. Germany HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 231. Germany HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 232. Germany HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 233. Germany HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 234. France HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 235. France HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 236. France HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 237. France HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 238. France HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 239. France HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 240. France HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. France HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 242. France HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 243. Russia HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 244. Russia HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 245. Russia HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 246. Russia HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 247. Russia HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 248. Russia HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 249. Russia HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 250. Russia HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 251. Russia HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. Italy HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 253. Italy HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 254. Italy HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 255. Italy HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 256. Italy HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 257. Italy HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 258. Italy HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. Italy HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 260. Italy HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 261. Spain HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 262. Spain HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 263. Spain HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 264. Spain HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 265. Spain HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 266. Spain HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 267. Spain HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 268. Spain HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 269. Spain HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 270. China HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 271. China HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 272. China HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 273. China HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 274. China HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 275. China HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 276. China HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 277. China HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 278. China HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 279. India HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 280. India HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 281. India HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 282. India HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 283. India HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 284. India HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 285. India HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 286. India HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 287. India HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 288. Japan HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 289. Japan HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 290. Japan HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 291. Japan HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 292. Japan HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 293. Japan HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 294. Japan HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 295. Japan HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 296. Japan HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 297. Australia HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 298. Australia HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 299. Australia HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 300. Australia HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 301. Australia HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 302. Australia HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 303. Australia HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 304. Australia HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 305. Australia HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 306. South Korea HAE Treatments Market Size, 2017-2032 (USD Million)
TABLE 307. South Korea HAE Treatments Market Size, by Therapy Mechanism, 2017-2032 (USD Million)
TABLE 308. South Korea HAE Treatments Market Size, by C1 Inhibitor Replacement, 2017-2032 (USD Million)
TABLE 309. South Korea HAE Treatments Market Size, by Kallikrein Inhibitor, 2017-2032 (USD Million)
TABLE 310. South Korea HAE Treatments Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 311. South Korea HAE Treatments Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 312. South Korea HAE Treatments Market Size, by End User, 2017-2032 (USD Million)
TABLE 313. South Korea HAE Treatments Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 314. South Korea HAE Treatments Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 315. Global HAE Treatments Market Share, by Key Player, 2025
TABLE 316. Global HAE Treatments Market, Key Experts

Companies Mentioned

  • Adverum Biotechnologies, Inc.
  • Akari Therapeutics plc
  • Alnylam Pharmaceuticals, Inc.
  • Argenx SE
  • AstraZeneca plc
  • Attune Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical Inc.
  • CSL Behring GmbH
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Homology Medicines, Inc.
  • IBio, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pharming Group N.V.
  • Regeneron Pharmaceuticals, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated

Related Topics

Related Reports

Hereditary Angioedema Therapeutics Market - Global Forecast 2026-2032 - Product Image

Hereditary Angioedema Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Plasma Protease C1-inhibitor Treatment - Global Strategic Business Report - Product Image

Plasma Protease C1-inhibitor Treatment - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Hereditary Angioedema Epidemiology Forecast 2026-2035 - Product Image

Hereditary Angioedema Epidemiology Forecast 2026-2035

  • Report
  • 150 Pages
  • Global
From
Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 177 Pages
  • Global
From
Kalbitor Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Kalbitor Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.